Lisa von Moltke

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Cambridge, MA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
By: /s/ Jeffrey Held, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Lisa von Moltke

Form 4 holding Director

Cara Therapeutics, Inc.

Security class
Common Stock
Shares / value
183,009
Estimated value
$137,257
Report date
04 Jun 2024
Price
$0.7500
Ownership
Direct
Form 4 holding Executive Vice President and Chief Medical Officer

Seres Therapeutics, Inc.

Security class
Common Stock
Shares / value
39,875
Estimated value
$32,319
Report date
18 Feb 2025
Price
$0.8105
Ownership
Direct
Form 4 holding Executive Vice President and Chief Medical Officer

Seres Therapeutics, Inc.

Security class
Restricted Stock Units
Shares / value
26,718
Estimated value
$14,446
Report date
15 Feb 2025
Price
$0.5407
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Executive Vice President and Chief Medical Officer

Seres Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
650,000
Estimated value
Report date
07 Feb 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Cara Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
195,000
Estimated value
Report date
04 Jun 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Head of Research and Development and Chief Medical Officer

Zenas BioPharma, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
150,000
Estimated value
Report date
15 Jun 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Lisa von Moltke

3 ZBIO

Zenas BioPharma, Inc.

Report period
17 Mar 2025
Transactions
0
Transaction value
$0
Accepted by SEC
21 Mar 2025, 16:01
Role
Head of Research and Development and Chief Medical Officer. Exhibit List: Exhibit 24 - Power of Attorney.
Next action
Open filing details
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .